AeroVanc in the Treatment of Methicillin-resistant Staphylococcus Aureus Infection in Patients With Cystic Fibrosis
Status:
Completed
Trial end date:
2021-01-15
Target enrollment:
Participant gender:
Summary
This is a multi-center, randomized phase III study to evaluate the clinical effectiveness of
AeroVanc in persistent methicillin-resistant Staphylococcus aureus (MRSA) infection in
patients with cystic fibrosis (CF).